Navigation Links
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
Date:3/4/2009

964 812,622 4,268,121 ------------------------------------------------------------------------- Cash used in operating activities (15,288,632) (14,422,092) (12,997,981) (88,204,848) ------------------------------------------------------------------------- INVESTING ACTIVITIES Acquisition of property and equipment (111,577) (92,221) (35,838) (813,744) Purchase of short-term investments (347,901) (949,496) (1,035,427) (49,416,864) Redemption of short-term investments 13,000,000 6,573,000 13,808,000 43,151,746 Investment in BCY LifeSciences Inc. - - - 464,602 Investment in Transition Therapeutics Inc. - - - 2,532,343 ------------------------------------------------------------------------- Cash provided by (used in) investing activities 12,540,522 5,531,283 12,736,735 (4,081,917) ------------------------------------------------------------------------- FINANCING ACTIVITIES Proceeds from exercise of stock options and warrants 41,600 51,000 241,400 15,301,068 Proceeds from private placements - - - 38,137,385 Proceeds from public offerings 3,421,309 12,063,394 - 46,278,207 ------------------------------------------------------------------------- Cash provided by financing activities 3,462,909 12,114,394 241,400 99,716,660 ------------------------------------------------------------------------- Net increase (decrease) in cash and cash equivalents during the period 714,799
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ... capital and general corporate purposes. Under ...
(Date:12/24/2014)... 23, 2014 SoundConnect’s ... designed to introduce cutting edge communication technology, ... partners of platform upgrades. This webinar series ... users in their quest to leverage web ... According to SoundConnect’s Marketing Manager, Seanna Baumgartner, ...
(Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... N.J., June 3 National Stem Cell,Holding, Inc. ... D. Steiner, MD, MBA, as its Chief Operating ... of proven management and business skills.,After establishing a ... a medical and business consultant to numerous Fortune ...
... June 3 Microtest Laboratories,( http://www.microtestlabs.com ) ... with the purchase of an additional MicroSeq(R),Microbial ... state-of-the-art DNA sequence-based system that,enables Microtest technicians ... that are not viable or easily identified., ...
... WILMINGTON, N.C., June 3 Inclinix, Inc. a ... for the,clinical trials of new drugs, today announced ... announced a growth rate of,40% in 2007 and ... which,came in January from Frontier Capital, a private ...
Cached Biology Technology:National Stem Cell Holding Appoints Kenneth Steiner, MD, MBA, as Chief Operating Officer 2National Stem Cell Holding Appoints Kenneth Steiner, MD, MBA, as Chief Operating Officer 3Microtest Labs Doubles Microbial Identification, Analytical Services 2Inclinix Expansion Creates New Position and Promotions 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... reductions, experts expect a sea-level rise of 40-60 centimeters by ... by a team of scientists from the USA and Germany. ... suggest a good chance of limiting future sea-level rise to ... of some coastal cities and low-lying islands," says Stefan Rahmstorf ...
... eventually leads to disability and a lower quality of ... rapidly or slowly. Scientists at ... identified a biochemical signal in the blood associated with ... help doctors predict early on, just after the onset ...
... dinosaur one of the three largest ever discovered in ... 98 million years ago. This newly discovered species, Siats ... time, and kept tyrannosaurs from assuming top predator roles for ... from Ute tribal legend, Siats is a species ...
Cached Biology News:Expert assessment: Sea-level rise could exceed 1 meter in this century 2UCLA, Emory researchers find a chemical signature for 'fast' form of Parkinson's 2Colossal new predatory dino terrorized early tyrannosaurs 2Colossal new predatory dino terrorized early tyrannosaurs 3
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... modified nucleotide structure called a ?cap? ... most naturally-occurring eukaryotic mRNAs and many ... for a portion of the GTP ... reaction results in the synthesis of ...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
This Dedicated 18" X 18" (45.7 X 45.7 cm.) shaker platforms are optimized for a particular flask clip size. Dedicated platforms come fully loaded with flask clips....
Biology Products: